- $18.55m
- -$50.77m
- $6.44m
FibroGen falls after Q4 revenue miss
UK Stocks-Factors to watch on Feb 27 (updated)
FibroGen Inc reports results for the quarter ended in December - Earnings Summary
FibroGen regains rights to anemia drug from AstraZeneca (updated)
FibroGen regains rights to anemia drug from AstraZeneca
Brief: Fibrogen Regains All Rights To Roxadustat From Astrazeneca In The United States And Other Astrazeneca Territories, Except China And South Korea
Brief: FibroGen Q4 EPS USD -0.57
FibroGen Inc expected to post a loss of 42 cents a share - Earnings Preview
FibroGen rises on mid-stage trial completion for cancer treatment
Brief: FibroGen Q3 EPS USD -0.65
FibroGen Inc expected to post a loss of 68 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Bradley, Apple, Salesforce
U.S. STOCKS ON THE MOVE-Energy firms, Gold miners, Tingo group
FibroGen hits record low after neuromuscular disorder therapy fails late-stage study
Brief: Fibrogen Announces Topline Results From Lelantos-2, A Phase 3 Clinical Study Of Pamrevlumab In Ambulatory Duchenne Muscular Dystrophy
FibroGen down as neuromuscular disorder drug fails in late-stage study
FibroGen Inc reports results for the quarter ended in June - Earnings Summary
Brief: FibroGen Q2 EPS USD -0.9
FibroGen Inc expected to post a loss of 70 cents a share - Earnings Preview